Please assess the completion status of the following clinical trial:

Trial Title: Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* HIV positive~* On stable HAART regimen for at least 6 months prior to study entry~* T-cell count greater than 100 and viral load less than 1,000 for at least 6 months prior to study entry~* Fasting triglyceride level greater than 150 mg/dl~* Body mass index (BMI) greater than 18.5 and less than 30~* Uses barrier contraception~Exclusion Criteria:~* Fasting triglyceride level greater than 1000 mg/dl~* BMI less than 18.5 or greater than 30~* Taking diabetic medication or HbA1c less than 7.0~* Use of lipid lowering medication in the 30 days prior to study entry~* Unable to exercise~* T-cell count less than 100~* Current medical condition that makes exercise unadvisable~* History of coronary artery disease (CAD)~* Use of dietary supplements (within 30 days of study entry) that may affect lipid levels including, but not limited to, the following:~  1. Omega-3 fatty acids~ 2. L-Carnitine~ 3. Soluble fiber supplements~ 4. Guggul~ 5. Garlic supplements~ 6. Niacin greater than 25mg/d~ 7. Oral liquid supplements~* Use of steroids, hormones, or testosterone (without diagnosis of hypogonadism, testosterone less than 300 ng/dl)~* Irregular periods~* Depo-Provera~* Hypo- or Hyperthyroidism~* Adrenal insufficiency~* Serum alanine or aspartate aminotransferase level greater than 3 times the upper limit of normal~* Alcohol abuse~* Renal insufficiency (creatinine level greater than 1.5 mg/dl)~* Coumadin therapy~* Pregnancy~* Peptic ulcer disease~* Cholelithiasis~* History of hyperuricemia~* History of myositis or rhabdomyolysis~* Known adverse reaction to niacin or fibrates~* Hepatitis C therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Subjects receive lifestyle advice and placebos for Niaspan and Tricor
- 2 (Type: EXPERIMENTAL): Diet, exercise, and two placebos
- 3 (Type: EXPERIMENTAL): Diet, exercise, Niaspan, and placebo
- 4 (Type: EXPERIMENTAL): Diet, exercise, placebo, and Tricor
- 5 (Type: EXPERIMENTAL): Diet, exercise, Niaspan, and Tricor

Based on this trial design, predict the completion outcome and termination type (if applicable).